1 2 3 4 5 6 7

Products

Description

GLYCIPHAGE® contains the active ingredient Metformin Hydrochloride, an oral anti-diabetic drug belonging to the biguanide class of molecules that decrease glucose production by the liver.

GLYCIPHAGE® overcomes insulin resistance and it has an extra-pancreatic peripheral action. GLYCIPHAGE® does not produce hypoglycaemia in either diabetic or non-diabetic subjects and does not cause hyperinsulinemia.

Metformin is approved and recommended by international guidelines from the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) as a first-line treatment for Type 2 Diabetes.

GLYCIPHAGE® also has additional possible beneficial effects such as

1. Weight reduction.
2. Lowering of plasma triglyceride levels.
3. Increase in plasma HDL cholesterol levels.
4. Increase in plasma fibrinolytic activity which has prophylactic and therapeutic value in various vascular complications of diabetes. e.g. Coronary artery disease, cerebrovascular accidents and peripheral vascular disease.

GLYCIPHAGE® TABLETS

 

(ORAL HYPOGLYCAEMIC AGENT)

Composition

GLYCIPHAGE®

Each uncoated tablet contains:
Metformin Hydrochloride I.P. ........................................500 mg.
Excipients ..................................................................... q.s.

click for enlarged image
 

GLYCIPHAGE® 850

Each uncoated tablet contains:
Metformin Hydrochloride I.P. ....................................... 850 mg.
Excipients ..................................................................... q.s.

click for enlarged image
 

GLYCIPHAGE® 250

Each uncoated tablet contains:
Metformin Hydrochloride I.P. ........................................250 mg.
Excipients ..................................................................... q.s.

click for enlarged image